Trial reportNeuropsychiatric disease and treatment2025
Association of Blood Pressure with Neurological Function Decline and Functional Outcome in Patients of Watershed Infarction.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The association between acute-phase blood pressure (BP) and outcomes in watershed infarction (WI) remains unclear. This study aimed to investigate the relationships between BP and BP changes with neurological functional decline (NFD) and functional outcome at 90 days. Methods: We included patients with WI from a prospective, observational, single-center study (Effect of Cardiac Function on Short-Term Functional Prognosis in Patients with Acute Ischemic Stroke, SPARK). We recorded data of systolic blood pressure (SBP) and diastolic blood pressure (DBP) on the day of admission, as well as on day 2 and day 3. In logistic regression models, both the baseline BP and BP changes were assessed. Results: Among the 207 patients with WI, 147 (71%) had concurrent cortical and internal infarcts. After adjusting for relevant factors, higher baseline SBP (OR:1.17; 95% CI:1.01-1.37) and DBP (OR:1.04; 95% CI:1.01-1.09) were associated with an increased risk of NFD. However, the restricted cubic spline (RCS) curve indicated that this association was statistically significant only when SBP was >180 mmHg or DBP was >100 mmHg. Additionally, an elevation in DBP of ≥4 mmHg on day 3 was associated with a reduced risk (OR:0.28; 95% CI: 0.08-0.97), whereas an elevation of DBP ≥10 mmHg was not. Neither baseline BP nor BP changes were associated with functional outcome. Conclusion: In patients with WI, the risk of NFD increases when baseline SBP >180 mmHg or DBP >100 mmHg. However, raising DBP by ≥4 mmHg but <10 mmHg on day 3 is associated with a reduced risk of NFD. BP may not be associated with functional outcome. Trial Registration: https://www.chictr.org.cn/, ChiCTR2300067696.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.